💉 This facility can produce 80 million doses annually. Collaborating with CordenPharma, they ensure a complete vaccine production pipeline.
🛠️ Their goal is rapid response to outbreaks, with flexible facility designs and trained staff ready for immediate action.
Introduction:
In an effort to enhance readiness for future pandemics, Wacker Biotech has established a competence center in Halle, Germany, dedicated to the production of mRNA vaccines. This initiative is part of a broader strategy initiated by the German Federal Ministry of Health to secure vaccine manufacturing capabilities within the country.
- Wacker Biotech and CordenPharma have partnered to create a production capacity of 80 million mRNA vaccine doses annually as part of Germany’s pandemic preparedness strategy.
- The establishment of the Center for Pandemic Vaccines and Therapeutics (ZEPAI) drives collaboration among pharmaceutical companies to secure local vaccine production.
- New facilities and expansions have been implemented at Wacker Biotech and CordenPharma to meet government requirements for domestic manufacturing and to reduce dependencies on global supply chains.
- Maximized flexibility in production is ensured through a modular design strategy and a state of constant readiness termed “warm base,” allowing for rapid deployment in a pandemic situation.
- Continued investment in technology, staff training, and production planning aims to maintain operational readiness while supporting ongoing customer projects and future pandemic responses.
Conclusion:
The proactive measures taken by Wacker Biotech, supported by significant government funding, position the company at the forefront of pandemic preparedness. By fostering local manufacturing capabilities and enhancing flexibility in production processes, the initiative not only addresses immediate public health needs but also sets a precedent for future responses to global health crises. Continued investment in biotechnological advancements and workforce development will be crucial to sustaining this readiness and facilitating swift production of vaccines as required.
